[268 Pages Report] The global anti-microbial/anti-fungal tests market is expected to reach US$ 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~US$ 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.
| Attributes | Key Insights |
|---|---|
| Anti-microbial/Anti-fungal Tests Market Value 2021 | US$ 2.4 Billion |
| Estimated Market Size 2022 | US$ 2.5 Billion |
| Projected Market Value 2032 | US$ 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Market Share of Top 5 Countries | 55.0% |
Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.
Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~US$ 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.
Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.
As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.
The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.
Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.
Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.
Principal Consultant
The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.
Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.
Growing Preference for Diagnostic Tests to Boost the Sales
The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.
Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China
China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.
Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.
It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.
Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection
Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.
This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond
Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.
Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.
Nearly 2 out of 5 Sales are Contributed by Hospitals
As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.
With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
| Attribute | Details |
|---|---|
| Estimated Market Size 2022 | US$ 2.5 Billion |
| Projected Market Value 2032 | US$ 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
| Key Market Segments Covered | Tests, Infection, End User, and Region |
| Key Companies Profiled |
|
The global anti-microbial/anti-fungal tests market is worth US$ 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.
The anti-microbial/anti-fungal tests market is expected to reach US$ 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.
The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.
USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.
North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.
Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.
Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.
China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.
Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.
1. Executive Summary | Anti-microbial/Anti-fungal Tests Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Epidemiology of Key Indication, By Region 4.2. Key Promotional Strategies 4.3. Patient Journey 4.4. Regulatory Scenario 4.5. Reimbursement Landscape 4.6. PESTEL analysis 4.7. Porter’s analysis 4.8. Value Chain 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare GDP Growth Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Prevalence of infectious diseases. 5.2.2. Increasing Awareness and Adoption. 5.2.3. Increase in rapid diagnostics tests. 5.2.4. Increasing prevalence of antimicrobial resistance patients. 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 5.4. Global Supply Demand Analysis 6. COVID-19 Crisis - Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.2. 2021 Market Scenario 6.2.1. By Tests Type 6.2.2. By Infection Type 6.2.3. By End User 6.2.4. By Region 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Tests Type, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests Type, 2022 to 2032 8.3.1. Molecular-Based Tests 8.3.1.1. PCR Test 8.3.1.2. DNA Microarray 8.3.2. Phenotypic Resistance Tests 8.3.3. Complex Test Panels 8.3.4. Mass Spectrometry 8.3.5. Rapid Diagnostic Tests 8.3.5.1. E-Test Antibiotic/Antifungal Strips 8.3.5.2. Biosensor Platforms 8.4. Market Attractiveness Analysis By Tests Type 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Infection Type, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Infection Type, 2022 to 2032 9.3.1. Antimicrobial Resistance 9.3.1.1. Methicillin-Resistant Staphylococcus Aureus 9.3.1.2. Vancomycin-Resistant Enterococcus 9.3.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis 9.3.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria 9.3.2. Microbial Infection 9.3.3. Antifungal Resistance 9.3.3.1. Candida infections 9.3.3.2. Aspergillus infection 9.3.3.3. Fusariosis 9.3.3.4. Others 9.3.4. Fungal Infection 9.4. Market Attractiveness Analysis By Infection Type 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032 10.3.1. Hospitals 10.3.2. Ambulatory Surgical Centers 10.3.3. Clinics 10.3.4. Community Health Centers 10.3.5. Reference Laboratories 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. United States of America 12.3.1.2. Canada 12.3.2. By Tests Type 12.3.3. By Infection Type 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Tests Type 12.4.3. By Infection Type 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country-Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Tests Type 12.8.1.2.2. By Infection Type 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Tests Type 12.8.2.2.2. By Infection Type 12.8.2.2.3. By End User 13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Tests Type 13.3.3. By Infection Type 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Tests Type 13.4.3. By Infection Type 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Tests Type 13.8.1.2.2. By Infection Type 13.8.1.2.3. By End User 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Tests Type 13.8.2.2.2. By Infection Type 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Tests Type 13.8.3.2.2. By Infection Type 13.8.3.2.3. By End User 14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United Kingdom 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Tests Type 14.3.3. By Infection Type 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Tests Type 14.4.3. By Infection Type 14.4.4. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Tests Type 14.8.1.2.2. By Infection Type 14.8.1.2.3. By End User 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Tests Type 14.8.2.2.2. By Infection Type 14.8.2.2.3. By End User 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Tests Type 14.8.3.2.2. By Infection Type 14.8.3.2.3. By End User 14.8.4. UK Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Tests Type 14.8.4.2.2. By Infection Type 14.8.4.2.3. By End User 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Tests Type 14.8.5.2.2. By Infection Type 14.8.5.2.3. By End User 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Tests Type 14.8.6.2.2. By Infection Type 14.8.6.2.3. By End User 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Tests Type 14.8.7.2.2. By Infection Type 14.8.7.2.3. By End User 15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Malaysia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Tests Type 15.3.3. By Infection Type 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Tests Type 15.4.3. By Infection Type 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Tests Type 15.8.1.2.2. By Infection Type 15.8.1.2.3. By End User 15.8.2. Indonesia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Tests Type 15.8.2.2.2. By Infection Type 15.8.2.2.3. By End User 15.8.3. Malaysia Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Tests Type 15.8.3.2.2. By Infection Type 15.8.3.2.3. By End User 15.8.4. Thailand Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Tests Type 15.8.4.2.2. By Infection Type 15.8.4.2.3. By End User 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Tests Type 16.3.3. By Infection Type 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Tests Type 16.4.3. By Infection Type 16.4.4. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Tests Type 16.8.1.2.2. By Infection Type 16.8.1.2.3. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Tests Type 16.8.2.2.2. By Infection Type 16.8.2.2.3. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Tests Type 16.8.3.2.2. By Infection Type 16.8.3.3. By End User 17. Oceania Market 2017 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Tests Type 17.3.3. By Infection Type 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Tests Type 17.4.3. By Infection Type 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Tests Type 17.8.1.2.2. By Infection Type 17.8.1.2.3. By End User 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Tests Type 17.8.2.2.2. By Infection Type 17.8.2.2.3. By End User 18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. North Africa 18.3.2. By Tests Type 18.3.3. By Infection Type 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Tests Type 18.4.3. By Infection Type 18.4.4. By End User 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Tests Type 18.8.1.2.2. By Infection Type 18.8.1.2.3. By End User 18.8.2. Turkey Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Tests Type 18.8.2.2.2. By Infection Type 18.8.2.2.3. By End User 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Tests Type 18.8.3.2.2. By Infection Type 18.8.3.2.3. By End User 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Tests Type 18.8.4.2.2. By Infection Type 18.8.4.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Abbott Laboratories 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Fey Financials 20.3.1.4. Sales Footprint 20.3.1.5. Strategy Overview 20.3.2. bioMérieux SA, 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Fey Financials 20.3.2.4. Sales Footprint 20.3.2.5. Strategy Overview 20.3.3. Bio-Rad Laboratories Inc., 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Fey Financials 20.3.3.4. Sales Footprint 20.3.3.5. Strategy Overview 20.3.4. Bruker Corporation, 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Fey Financials 20.3.4.4. Sales Footprint 20.3.4.5. Strategy Overview 20.3.5. Danaher Corporation, 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Fey Financials 20.3.5.4. Sales Footprint 20.3.5.5. Strategy Overview 20.3.6. Erba Mannheim, 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Fey Financials 20.3.6.4. Sales Footprint 20.3.6.5. Strategy Overview 20.3.7. F. Hoffmann-La Roche AG, 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Fey Financials 20.3.7.4. Sales Footprint 20.3.7.5. Strategy Overview 20.3.8. Luminex Corporation, 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Fey Financials 20.3.8.4. Sales Footprint 20.3.8.5. Strategy Overview 20.3.9. Meridian Bioscience Inc., 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Fey Financials 20.3.9.4. Sales Footprint 20.3.9.5. Strategy Overview 20.3.10. Norgen Biotek Corp., 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Fey Financials 20.3.10.4. Sales Footprint 20.3.10.5. Strategy Overview 20.3.11. Omega Diagnostics Group Plc., 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Fey Financials 20.3.11.4. Sales Footprint 20.3.11.5. Strategy Overview 20.3.12. Qiagen N.V., 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Fey Financials 20.3.12.4. Sales Footprint 20.3.12.5. Strategy Overview 20.3.13. Quidel Corporation, 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Fey Financials 20.3.13.4. Sales Footprint 20.3.13.5. Strategy Overview 20.3.14. Thermo Fisher Scientific Inc. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Fey Financials 20.3.14.4. Sales Footprint 20.3.14.5. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Healthcare
February 2022
REP-GB-607
October 2023
183 pages
Explore Healthcare Insights
View Reports
Anti-microbial/Anti-fungal Tests Market
